## CLX: Clorox Company (The) - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -1.6% below STRENGTH zone (4.0-10.0%); PEG 3.35 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Hudson Bay Capital Management LP Makes New $8.57 Million Investment in The Clorox Company $CLX**
- Source: MarketBeat | 20251215T105909 | Somewhat-Bullish | Relevance: 100%
- Hudson Bay Capital Management LP has invested $8.57 million in The Clorox Company by purchasing 71,362 shares, representing about 0.06% ownership. This move follows Clorox beating its quarterly EPS estimates and setting FY2026 guidance, alongside a director's significant share purchase. Institutional investors and hedge funds own 78.53% of Clorox stock.

**2. Clorox Co. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains**
- Source: 富途牛牛 | 20251215T170756 | Somewhat-Bearish | Relevance: 100%
- Clorox Co. stock underperformed on Friday compared to its competitors despite daily gains. The article mentions Unity Software's recent Q4 earnings, where revenue increased 35% year-over-year to $609 million, beating estimates, though the company reported a quarterly loss of 66 cents per share. The full details for Clorox's performance are behind a login or sign-up wall due to copyright restrictions.

**3. Stance Capital LLC Acquires New Stake in The Clorox Company $CLX**
- Source: MarketBeat | 20251214T125005 | Neutral | Relevance: 100%
- Stance Capital LLC has acquired a new stake in The Clorox Company ($CLX), purchasing 12,989 shares valued at approximately $1,560,000. This move is part of broader institutional investor activity, with several other hedge funds also adjusting their holdings in Clorox. The company recently reported Q3 earnings that beat analyst estimates and declared a quarterly dividend of $1.24 per share.

**4. My 3 Favorite Dividend Stocks to Buy Right Now**
- Source: Finviz | 20251215T102329 | Somewhat-Bullish | Relevance: 90%
- The author recommends three consumer staples companies—Clorox, Hershey, and General Mills—as attractive dividend stocks. These businesses are considered resilient due to their essential products and strong brands, offering historically high dividend yields despite current inflationary pressures and other headwinds. The article suggests they are currently undervalued and could be good long-term investments for those with a contrarian view.

**5. UV Infection Control Devices Market to Grow at 6.5% CAGR During 2024-2031; North America Leads with 39% Share - Key Players: STERIS, Getinge, Xenex**
- Source: openPR.com | 20251216T090826 | Somewhat-Bullish | Relevance: 72%
- The global UV Infection Control Devices Market is projected to grow at a CAGR of 6.5% from 2024 to 2031, driven by increasing awareness of hospital-acquired infections, a focus on hygiene, and the adoption of non-chemical disinfection technologies. North America, particularly the U.S. and Canada, is expected to hold the largest market share due to advanced healthcare infrastructure and strict regulations. Key market players include STERIS plc., Getinge Group, and Xenex, who lead in providing various UV-C disinfection solutions for healthcare and public settings.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($9.83M) |
| Sells | 4 ($1.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Valuation stretched: PEG 3.3x requires aggressive growth execution.
2. Long-term trend broken: trading 19.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.35 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Insider buying signal ($9.8M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.4B |
| Beta | 0.57 |
| 52W Range | $98.20 - $165.12 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.35 |
| Forward P/E | 15.1 |
| Current P/E | 17.0 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.5% to -1.6% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.8%) - potential reversal signal. Underperforming sector by 3.6pp, stock-specific weakness. Below SMA200 (0.81x), long-term trend not supportive. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.61% (CS: 23) | Neutral |
| RSI_14 | 38.7 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 0.927x | Below |
| vs SMA200 | 0.809x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.72
- **Stop Loss:** $96.96 (4.7% risk)
- **Target:** $106.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 252
- **Position Value:** $25,633.44
- **Portfolio %:** 25.63%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*